Biosyent (TSXV:RX) Beginning Cash Position : C$7.98 Mil (As of Mar. 2024)

View and export this data going back to 1979. Start your Free Trial

What is Biosyent Beginning Cash Position?

Biosyent's Beginning Cash Position for the quarter that ended in Mar. 2024 was C$7.98 Mil.

Biosyent's quarterly Beginning Cash Position increased from Sep. 2023 (C$9.30 Mil) to Dec. 2023 (C$9.67 Mil) but then declined from Dec. 2023 (C$9.67 Mil) to Mar. 2024 (C$7.98 Mil).

Biosyent's annual Beginning Cash Position declined from Dec. 2021 (C$20.29 Mil) to Dec. 2022 (C$18.04 Mil) and declined from Dec. 2022 (C$18.04 Mil) to Dec. 2023 (C$7.87 Mil).

Biosyent Beginning Cash Position Historical Data

The historical data trend for Biosyent's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Beginning Cash Position Chart

Biosyent Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

16.83

13.44

20.29

18.04

7.87

Biosyent Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															7.86	6.42	9.30	9.67	7.98

Biosyent Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Biosyent Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Biosyent's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent (TSXV:RX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BIOYF:USA

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Executives

Peter Douglas Lockhard

Director

Biosyent (TSXV:RX) Headlines

No Headlines